(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement following the Trump Administration’s announcement on lowering prices on GLP-1 products.

“America’s pharmacy benefit managers (PBMs) applaud the Trump Administration for continuing to hold Big Pharma accountable for the egregious prices they set on brand-name drugs in the United States, especially for GLP-1 medications for diabetes and weight loss.

“PBMs will continue to support lower drug prices for the American people as well as options in the marketplace for health plans and patients to access affordable medications.

“Today’s announcement once again confirms that Big Pharma can lower list prices of prescription drugs at any time. The sticker price is the starting point for all PBM and drug company negotiations – and often the basis for cost-sharing obligations. Rising drug prices limit the ability of PBMs to effectively secure savings to address the affordability challenge that some patients face. A lower sticker price means employers, unions, plan sponsors, and most importantly, patients, will pay less.

“For health plans covering GLP-1s for weight loss, PBMs offer programs to help patients make permanent lifestyle changes, including diet and exercise, alongside using GLP-1s.”

Learn more about how PBMs are working to lower the costs of GLP-1 drugs HERE.

###

PCMA is the national association representing America’s pharmacy benefit companies. Pharmacy benefit companies are working every day to secure savings, enable better health outcomes, and support access to quality prescription drug coverage for more than 289 million patients.